Members of Congres patient advocate...

Members of Congres patient advocates, and a certain number of industry experts say it is time to re-evaluate commons and Drug Administration approval and postapproval operations. Safety belong tos about prescription drugs continue to soar along with charges that recent drugs are coming to market without adequate testing and that postmarket surveillance has pocketed Some legislators want to give FDA authority to require postapproval studies and labeling revisions. FDA officials maintain that freshly proposed internal initiatives can fix most numerous of its problems.

The Senate Health, Education, Labor,